Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

Clinical trial NCT07668960 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07668960
Sponsor: Shanghai Mianyi Biopharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection

Start date: 2026-06-17
Primary completion: 2029-12-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.